glutamic acid has been researched along with Left Ventricular Dysfunction in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Friberg, Ö; Håkanson, E; Holm, J; Svedjeholm, R; Tajik, B; Vanky, F; Vidlund, M | 1 |
| Amorim, PA; Doenst, T | 1 |
| Håkanson, E; Svedjeholm, R; Vanhanen, I; Vidlund, M | 1 |
| Borg, JO; Friberg, O; Håkanson, E; Holm, J; Juhl-Andersen, S; Sharma, R; Sunnermalm, L; Svedjeholm, R; Vanky, F; Vidlund, M | 1 |
| Barry, J; Chen, AP; Clarke, K; Connelly, KA; Cunningham, CH; Dyck, JR; Gu, Y; Hu, X; Lau, AZ; Nagendran, J; Schroeder, MA; Tyler, DJ; Wright, GA | 1 |
2 trial(s) available for glutamic acid and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Post hoc analysis of the glutamics-trial: intravenous glutamate infusion and use of inotropic drugs after cabg.
Topics: Acute Coronary Syndrome; Aged; Cardiotonic Agents; Coronary Artery Bypass; Double-Blind Method; Epinephrine; Female; Glutamic Acid; Heart Failure; Humans; Infusions, Intravenous; Male; Middle Aged; Postoperative Complications; Ventricular Dysfunction, Left | 2016 |
GLUTAMICS--a randomized clinical trial on glutamate infusion in 861 patients undergoing surgery for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Coronary Artery Bypass; Double-Blind Method; Female; Glutamic Acid; Heart Failure; Humans; Infusions, Intravenous; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Prospective Studies; Risk Assessment; Risk Factors; Sodium Chloride; Sweden; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
3 other study(ies) available for glutamic acid and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Metabolic therapy in cardiac surgery--"Optimizing the engine's fuel supply and more...".
Topics: Adenosine Triphosphate; Cardioplegic Solutions; Coronary Artery Bypass; Energy Metabolism; Glucose; Glutamic Acid; Heart Failure; Humans; Insulin; Myocardial Contraction; Myocardial Ischemia; Myocardium; Potassium; Recovery of Function; Treatment Outcome; Ventricular Dysfunction, Left | 2010 |
A metabolic protective strategy could improve long-term survival in patients with LV-dysfunction undergoing CABG.
Topics: Aged; Cardioplegic Solutions; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Bypass; Energy Metabolism; Female; Glucose; Glutamic Acid; Heart Failure; Humans; Insulin; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Contraction; Myocardial Ischemia; Myocardium; Oxygen Consumption; Potassium; Recovery of Function; Risk Assessment; Risk Factors; Severity of Illness Index; Stroke Volume; Sweden; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2010 |
Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart.
Topics: Adenosine Triphosphate; Animals; Bicarbonates; Carbon Isotopes; Cardiac Pacing, Artificial; Cardiac Volume; Cardiomyopathy, Dilated; Carnitine O-Palmitoyltransferase; Citric Acid Cycle; Disease Models, Animal; Energy Metabolism; Gene Expression; Glutamic Acid; Glycolysis; Heart Failure; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Membrane Transport Proteins; Phosphocreatine; PPAR alpha; Protein Kinases; Pyruvate Dehydrogenase Complex; Pyruvic Acid; Swine; Ventricular Dysfunction, Left | 2013 |